Technology | Interventional Radiology | August 16, 2019

U.S. commercial launch of transurethral prostate tissue ablation system combining MRI and ultrasound expected in the fourth quarter of 2019

Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro

August 16, 2019 — Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.

Tulsa-Pro is a transurethral prostate tissue ablation system that combines real-time magnetic resonance imaging (MRI) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue. The Tulsa-Pro system is designed to provide customizable and predictable, incision-free and radiation-free prostate ablation while actively protecting the urethra and rectum with water cooling to preserve men’s functional abilities.

The FDA’s clearance of Tulsa-Pro was based on the company’s TACT pivotal clinical trial, which met all of its primary and secondary efficacy and safety endpoints. TACT enrolled 115 patients across the United States, Canada and Europe with biopsy-proven, organ-confined prostate cancer (67 percent and 33 percent of subjects had NCCN intermediate- and low-risk disease, respectively). All patients received primary treatment of whole-gland prostate ablation with sparing of the urethra and urinary sphincter. TACT demonstrated that the Tulsa-Pro provides safe and effective prostate tissue ablation, with minimal adverse events, significant prostate volume and prostate specific antigen (PSA) reduction, and low rates of residual prostate disease. The favorable safety profile offered by the Tulsa-Pro contrasts with radical prostatectomy and radiation therapy that can leave many men with permanent erectile dysfunction, urinary incontinence and bowel dysfunction. The TACT study also demonstrated a favorable risk-benefit profile in the context of other ablative approaches, including whole-gland high intensity focused ultrasound (HIFU) and cryotherapy.

The FDA label for Tulsa-Pro will allow U.S. surgeons to perform prostate tissue ablation procedures indiscriminate of tissue type, including malignant and benign.

“We are pleased with the FDA’s expeditious review of our application,” said Arun Menawat, Profound’s CEO. “We believe this, combined with the label that the Agency approved for TULSA-PRO®, serves as a testament to our technology’s strong clinical profile.”

Profound Medical CEO Arun Menawat said the company is preparing for the U.S. commercial launch of Tulsa-Pro in the fourth quarter of 2019. 

For more information: www.profoundmedical.com

Related Content

Profound Medical Corp. Announces First Paid Procedure Using TULSA-PRO System

Profound Medical Corp. and Philips Announce First TULSA-PRO Sale in Finland

Related Content

News | Magnetic Resonance Imaging (MRI)

December 1, 2021 — In the first MRI-based study to investigate prenatal alcohol exposure, researchers found significant ...

Time December 01, 2021
arrow
News | Coronavirus (COVID-19)

November 30, 2021 — COVID-19 of mild to moderate severity in pregnant women appears to have no effect on the brain of ...

Time November 30, 2021
arrow
News | Coronavirus (COVID-19)

November 29, 2021 — The largest multi-institutional international study to date on brain complications of COVID-19 has ...

Time November 29, 2021
arrow
News | Coronavirus (COVID-19)

November 29, 2021 — A small but significant percentage of college athletes with COVID-19 develop myocarditis, a ...

Time November 29, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 24, 2021 — Royal Philips announced new AI-enabled innovations in MR imaging launching at the Radiological ...

Time November 24, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
News | Interventional Radiology

November 23, 2021 — A minimally invasive ablation procedure offers long-term relief for patients who experience chronic ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 22, 2021 — Adolescents and young adults with post-concussive symptoms who suffered three to five concussions ...

Time November 22, 2021
arrow
News | Ultrasound Imaging

November 18, 2021 — Royal Philips, a leader in health technology, announced it has received 510(k) clearance from the U ...

Time November 18, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 17, 2021 — The University of Michigan Health System recently became the first U.S. healthcare institution to ...

Time November 17, 2021
arrow
Subscribe Now